A randomized phase II study of bevacizumab (NSC 704865) and gemcitabine in combination with either cetuximab (NSC 714692) or OSI 774 (NSC 718781) [erlotinib] in patients with advanced pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2013
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 30 Aug 2005 New trial record.